SLC39A11 and leukemia: We highlight the highly expressed ZIP11 in AML, which is located in the nucleus for nuclear zinc release, leads to the low nuclear zinc level, and should be inhibited for leukemia therapy.[56] ZIP8, which is expressed on lysosomes, plays a role in promoting zinc release, potentially benefiting the zinc nanoparticle‐involved strategy.